Disparities
-
Why Do African Americans Have Increased Breast Cancer Mortality?Socioeconomic factors and racism can lead to poorer health outcomes for Black Americans. Genetics may also be a factor behind increased mortality rates.
by Marci A. Landsmann
-
From the Editor-in-Chief
Cancer in Minority PopulationsPaying attention to the social determinants of health will promote greater equity in cancer outcomes for all.
by William G. Nelson, MD, PhD
-
Forward Look
Creating More Inclusive Clinical TrialsThe Clinical Treatment Act aims to include more Medicaid recipients.
by Jen Tota McGivney
-
Forward Look
Cancer Screening for the LGBTQ CommunityFear of discrimination may lead to lower screening rates.
by Tara Santora
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical TrialsThe AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
COVID-19 Exposes Health InequitiesAt a symposium held during a virtual meeting of cancer researchers, panelists discussed the disproportionate impact COVID-19 has had on Black and Latino Americans, as well as members of other minority groups.
by Kevin McLaughlin
-
Pediatric Oncologists Underestimate Needs of Minority ParentsResearch describes how communication gaps can shift extra burden to parents who are members of ethnic and racial minority groups.
by Marci A. Landsmann
-
Pushing Progress ForwardNCI Director Norman E. “Ned” Sharpless addresses disparities and maps out plans for the future amid “profound upheaval.”
by Kevin McLaughlin
-
Policy Matters
Taking Steps to Address Cancer Health DisparitiesCancer outcomes are changing for the better, but advances are not affecting all patients equally.
by Brian Rivers, PhD
-
BRCA: Who Should Be Tested?Genetic testing for mutations in the BRCA1 and BRCA2 genes creates opportunities for cancer risk reduction. But 25 years after the mutations were discovered, some who could benefit from testing are still left out.
by Sue Rochman
